LIVE WEBINAR: Tuesday, January 11, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Targeted Therapy for Non-Small Cell Lung Cancer

Join us on Tuesday, January 11th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Tuesday, January 11, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Management of Non-Small Cell Lung Cancer with an EGFR, ALK or ROS1 Abnormality
  • PART II: Therapeutic Approaches for Patients with Actionable Genomic Alterations Beyond EGFR, ALK and ROS1

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider emerging research information and available guideline recommendations to individualize first- and later-line therapy for patients with non-small cell lung cancer (NSCLC) harboring various targetable genetic abnormalities.
  • Acknowledge the FDA approval of adjuvant osimertinib for early-stage NSCLC with an EGFR mutation, and identify individuals for whom treatment with this novel approach would be warranted.
  • Develop an optimal approach to the management of newly diagnosed metastatic NSCLC with an EGFR mutation, considering the implications of mutation type, symptomatology, sites and extent of metastases and other relevant factors.
  • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive disease and an EGFR mutation.
  • Understand the biology of EGFR exon 20 insertion mutations and optimally incorporate recently approved agents into the care of patients with these abnormalities.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC.
  • Convey the clinical relevance of a positive ROS1 mutation testing result to appropriate patients with NSCLC, and appreciate available clinical research findings with approved and investigational agents demonstrating efficacy in these individuals.
  • Assess available research evidence with approved RET inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive NSCLC.
  • Evaluate available clinical trial findings supporting the FDA approval of novel MET inhibitors for patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping and identify those who might benefit from treatment with these novel compounds.
  • Recall other oncogenic pathways (eg, NTRK, KRAS G12C, HER2) mediating the growth of tumors in unique subsets, and consider published and emerging data with commercially available and investigational agents exploiting these targets.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr HeymachAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, RefleXion, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Spectrum Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: BrightPath Biotherapeutics Co Ltd; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc; Speaker's Bureau: IDEOlogy Health. Dr PiotrowskaAdvisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medtronic Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.